UNASSIGNED: Wound healing is a physiological reparative response to injury and a well-orchestrated process that involves hemostasis, cellular migration, proliferation, @entity7499 , extracellular matrix deposition, and wound contraction and re-epithelialization. However, @entity1 with @entity6 ( @entity6 ) are frequently afflicted with @entity73 that progresses into chronic wounds or @entity6 , and may lead to complications including limb amputation. Herein, we investigate the potential role of microRNA-26a ( @entity47695 ) in a @entity6 model of wound healing. Expression of @entity47695 is rapidly induced in response to high @entity413 in endothelial cells (ECs). Punch skin biopsy wounding of db/db @entity19 revealed increased expression of @entity47695 (~3.5-fold) four days post-wounding compared to that of @entity7097 @entity19 . Local administration of a @entity47695 inhibitor, LNA-anti- @entity47695 , induced @entity7499 (up to ~80%), increased granulation tissue thickness (by 2.5-fold) and accelerated wound closure (53% after nine days) compared to scrambled anti- @entity21445 controls in db/db @entity19 . These effects were independent of altered M1/M2 macrophage ratios. Mechanistically, inhibition of @entity47695 increased its target gene @entity14901 in ECs nine days post-wounding of @entity6 @entity19 . In addition, high @entity413 reduced activity of the @entity14901 -3'-UTR. @entity6 dermal wounds treated with LNA-anti- @entity47695 had increased expression of @entity21391 , a downstream modulator or @entity14901 , and decreased expression of the cell cycle inhibitor @entity7919 . These findings establish @entity47695 as an important regulator on the progression of @entity272 of @entity6 @entity19 by specifically regulating the angiogenic response after injury, and demonstrate that neutralization of @entity47695 may serve as a novel approach for therapy.

Regulation of @entity73 in XXXX dermal wound healing by microRNA-26a.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity14901 :: ('17125(Tax:10090)', 'Gene') :: ['SMAD1'] @entity7499 :: ('MESH:D016510', 'Disease') :: ['angiogenesis'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic ulcers', 'Diabetic', 'diabetic', 'T2D', 'type 2 diabetes mellitus'] @entity7919 :: ('12576(Tax:10090)', 'Gene') :: ['p27'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired wound healing'] @entity7097 :: ('MESH:C536751', 'Disease') :: ['WT'] @entity21391 :: ('15901(Tax:10090)', 'Gene') :: ['ID1'] @entity47695 :: ('387218(Tax:10090)', 'Gene') :: ['miR-26a'] @entity21445 :: ('751557(Tax:10090)', 'Gene') :: ['miR'] @entity272 :: ('MESH:D012871', 'Disease') :: ['skin wounds'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity6 :: (MESH:D003920,Disease) :: ['diabetic']
